Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Geron Corp (GERN)
NASDAQ:GERN
Geron (GERN) Stock Price & Analysis
2,035 Followers
GERN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.64 - $5.34
Previous Close$4.6
Volume4.16M
Average Volume (3M)11.47M
Market Cap
$2.73B
Enterprise Value$2.37B
Total Cash (Recent Filing)$443.05M
Total Debt (Recent Filing)$86.53M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Aug 08, 2024EPS Estimate
-$0.1Last Dividend Ex-Date
Jul 22, 2014Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding593,132,540
10 Day Avg. Volume25,477,863
30 Day Avg. Volume11,474,036
Standard Deviation0.18
R-Squared0.02
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)11.12
Price to Sales (P/S)9072.59
Price to Cash Flow (P/CF)-16.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.56K
Enterprise Value/Gross Profit10.01K
Enterprise Value/Ebitda-12.06
Forecast
1Y Price Target
$7.07Price Target Upside53.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Geron News
Bulls Say, Bears Say
Bulls Say
FDA ApprovalThe FDA approved Geron's Rytelo (imetelstat) in low/intermediate-risk myelodysplastic syndrome (LR-MDS) patients.
Market PotentialRytelo has $1.8bn potential in MDS with a broad 2L label, compelling positioning given the unmet need, and attractive pricing supporting a robust launch.
Safety ProfileRytelo's label has no Black Box warnings, and patients/physicians will not be required to participate in a REMS program.
Bears Say
Clinical TrialsTimelines for Phase 3 IMpactMF trial extended; probability of success lowered to 40%.
Regulatory ApprovalApproval is nearly 100% priced in, and the stock could be slightly pressured around the time of approval.
Stock PerformanceStock is unlikely to trade much higher from here over the coming months unless the company is acquired.
---
Ownership Overview
1.77% Insiders
9.27% Mutual Funds
13.77% Other Institutional Investors
75.18% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GERN FAQ
What was Geron Corp’s price range in the past 12 months?
Geron Corp lowest stock price was $1.64 and its highest was $5.34 in the past 12 months.
What is Geron Corp’s market cap?
Currently, no data Available
When is Geron Corp’s upcoming earnings report date?
Geron Corp’s upcoming earnings report date is Aug 08, 2024 which is in 18 days.
How were Geron Corp’s earnings last quarter?
Geron Corp released its earnings results on May 02, 2024. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.096 by $0.006.
Is Geron Corp overvalued?
According to Wall Street analysts Geron Corp’s price is currently Undervalued.
Does Geron Corp pay dividends?
Geron Corp pays a Notavailable dividend of $0.15 which represents an annual dividend yield of N/A. See more information on Geron Corp dividends here
What is Geron Corp’s EPS estimate?
Geron Corp’s EPS estimate is -$0.1.
How many shares outstanding does Geron Corp have?
Geron Corp has 593,132,570 shares outstanding.
What happened to Geron Corp’s price movement after its last earnings report?
Geron Corp reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.096. Following the earnings report the stock price went down -3.186%.
Which hedge fund is a major shareholder of Geron Corp?
Among the largest hedge funds holding Geron Corp’s share is RA Capital Management. It holds Geron Corp’s shares valued at 152M.
---
Geron Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.07 (53.70% Upside)
$7.07 (53.70% Upside)
Blogger Sentiment
Bullish
GERN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 16.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.97%
12-Months-Change
Fundamentals
Return on Equity
-60.04%
Trailing 12-Months
Asset Growth
13.46%
Trailing 12-Months
Company Description
Geron Corp
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.
---
GERN Company Deck
---
GERN Earnings Call
Q1 2024
0:00 / 0:00
---
GERN Stock 12 Month Forecast
Average Price Target
$7.07
▲(53.70% Upside)
Technical Analysis
Best Analysts Covering GERN
1 Year
---